Zekun Li

Zekun Li

Auto-generated profile, based on publicly available information

Zekun Li

Tianjin Medical University Cancer Institute and Hospital 3 Department of Pancreatic Cancer, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer Tianjin, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2026 in Cancer Letters
Verified
Journal Article
Closed access
ZZZewei Zhao
Zewei Zhao
WJWenbin Jia
Wenbin Jia
ZLZekun Li
Zekun Li
SSShangheng Shi
Shangheng Shi
JZJiaqi Zhou
Jiaqi Zhou
YYYue Yu
Yue Yu

8 July 2026 in Cancer Discovery
Verified
Journal Article
Closed access
TZTianxing Zhou
Tianxing Zhou
JYJingrui Yan
Jingrui Yan
GMGuohua Mao
Guohua Mao
YZYu Zhang
Yu Zhang
SSShangheng Shi
Shangheng Shi
JHJihui Hao
Jihui Hao
Lymph node (LN) metastasis (LNM) in early-stage pancreatic ductal adenocarcinoma (PDAC) predicts systemic dissemination and poor survival, yet its underlying mechanisms remain elusive. In this study, we demonstrated that senescent cancer-associated fibroblasts (senCAF) drive lymphatic remodeling and LNM in early-stage PDAC. Mechanistically, senCAFs increased glucose metabolism and lactate production, which activated lactylation-mediated serine metabolism to protect lymphatic endothelial cells from oxidative stress. Moreover, we discovered CCR4+ regulatory T cells from the draining LNs accumulated around lymphatic vessels, which established an immunosuppressive perilymphatic niche. High-throughput drug screening determined selective clearance of senCAFs via chidamide, attenuated tumor progression, and improved chemoimmunotherapeutic efficacy. We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti–PD-1/CTLA-4) in patients with metastatic PDAC and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemoimmunotherapy efficacy. Significance: Our findings have revealed a closed link between cellular senescence, metabolic reprograming, and spatial immunosuppressive niche and PDAC metastasis, offering the potential senolytic drugs to improve chemoimmunotherapy efficacy in patients with PDAC.

3 November 2026 in Cancer Research
Verified
Journal Article
Closed access
MZMengzhe Zhang
Mengzhe Zhang
ZLZekun Li
Zekun Li
ZXZengtuan Xiao
Zengtuan Xiao
SJShuai Jiang
Shuai Jiang
YDYiying Di
Yiying Di
ZZZhenfa Zhang
Zhenfa Zhang
A substantial proportion of patients with treatment-naïve lung adenocarcinoma (LUAD) exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. In this study, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in nonresponders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T-cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3–cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD. Significance: Targeting CHCHD3 activates cGAS-STING signaling to stimulate anti-tumor immunity and sensitize lung cancer to chemoimmunotherapy, highlighting the therapeutic potential of this approach to improve patient outcomes.

3 August 2026
Verified
Other
Open access
TZTianxing Zhou
Tianxing Zhou
JYJingrui Yan
Jingrui Yan
GMGuohua Mao
Guohua Mao
YZYu Zhang
Yu Zhang
SSShangheng Shi
Shangheng Shi
JHJihui Hao
Jihui Hao
Supplementary Table 2 shows the patient characteristics in the proof-of-concept clinical trial; Supplementary Table 3 shows treatment-related adverse events in the proof-of-concept clinical trial.